Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

20,638 total articles

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Mar 25, 2026
Jordan Park
Press Releases

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics has dosed the first patient in a Phase 1b trial evaluating the combination of their oral IKZF1/3 degrader cemsidomide with elranatamab (ELREXFIO®), an FDA-approved bispecific antibody, in patients with relapsed or refractory multiple myeloma. The trial aims to establish the optimal dose, assess safety, tolerability, and preliminary …

CCCC
Energous Wireless Power Solutions Reports Fiscal Year 2025 Results
Mar 25, 2026
Hana Yamamoto
Press Releases

Energous Wireless Power Solutions Reports Fiscal Year 2025 Results

Energous Corporation announced strong fiscal year 2025 results, reporting $5.6 million in revenue — a 633% increase from 2024 — and the lowest quarterly net loss since 2013. The company achieved four consecutive quarters of revenue growth, expanded production capacity in the U.S., and secured a large expansion with a Fortune 10 retailer. Operationa…

WATT
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Mar 25, 2026
Leila Farooq
Press Releases

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam Therapeutics announced updated clinical data from its ongoing Phase 1/2 trial of BEAM-302, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The therapy showed a well-tolerated safety profile and durable increases in functional AAT protein with significant reduction in mutant Z-AAT after a single dose. Beam selected 60 mg as th…

BEAM
Winnebago Industries Reports Second Quarter Fiscal 2026 Results
Mar 25, 2026
Hana Yamamoto
Press Releases

Winnebago Industries Reports Second Quarter Fiscal 2026 Results

Winnebago Industries, a leading manufacturer in outdoor recreation products, reported a 6% increase in net revenues to $657.4 million for Q2 Fiscal 2026 and significant profitability improvements, including a 42.1% rise in adjusted earnings per diluted share to $0.27. The company improved operating income by 50.7% to $11.8 million and executed a $1…

WGO
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Mar 25, 2026
Nina Shah
Press Releases

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Merck & Co., Inc. announced an agreement to acquire Terns Pharmaceuticals, a clinical-stage oncology company, for approximately $6.7 billion. The acquisition focuses on Terns' lead investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, TERN-701, which is in Phase 1/2 trials for chronic myeloid leukemia (CML). The deal reflects Merck's…

MRK TERN
BOSS Zhipin Continues Share Repurchase Program; Cumulative Repurchases Reach Nearly RMB450 Million in FY26
Mar 25, 2026
Avery Klein
Press Releases

BOSS Zhipin Continues Share Repurchase Program; Cumulative Repurchases Reach Nearly RMB450 Million in FY26

Kanzhun Limited, operating as BOSS Zhipin, announced the continuation and expansion of its share repurchase program, having spent nearly RMB450 million in 2026 to buy back shares. The board increased repurchase authorization to US$400 million through August 2027 and committed to allocating at least 50% of adjusted net income annually for dividends …

BZ
ADMA Biologics Addresses Misleading Short-Seller Report
Mar 25, 2026
Ajmal Hussain
Press Releases

ADMA Biologics Addresses Misleading Short-Seller Report

ADMA Biologics, a U.S.-based biopharmaceutical company specializing in plasma-derived biologics for immune deficiencies, has publicly addressed a negative short-seller report issued by Culper Research. The company refutes the report's assertions as speculative and false, emphasizing its compliance with regulatory standards and ongoing review of the…

ADMA
Comstock to Participate in the Lytham Partners 2026 Industrials & Basic Materials Investor Summit on April 1, 2026
Mar 25, 2026
Hana Yamamoto
Press Releases

Comstock to Participate in the Lytham Partners 2026 Industrials & Basic Materials Investor Summit on April 1, 2026

Comstock Inc. announced that it will participate in a webcast presentation at the Lytham Partners 2026 Industrials & Basic Materials Investor Summit scheduled for April 1, 2026. The company continues to focus on innovative technologies that extract and recycle critical metals from end-of-life photovoltaics, supporting clean energy systems.

LODE
Viomi Technology Co., Ltd Reports Second Half and Full Year 2025 Unaudited Financial Results and Announces Special Dividend
Mar 25, 2026
Hana Yamamoto
Press Releases

Viomi Technology Co., Ltd Reports Second Half and Full Year 2025 Unaudited Financial Results and Announces Special Dividend

Viomi Technology Co., Ltd, a NASDAQ-listed Chinese home water solutions company, announced unaudited financial results for H2 and full-year 2025, showing a 14.6% revenue increase to RMB2.43 billion for the year despite a 25.9% revenue decline in the second half. Net income dipped slightly by 1.9% year-over-year to RMB141.6 million. The company attr…

VIOT
Diversified Files Definitive Proxy Materials
Mar 25, 2026
Leila Farooq
Press Releases

Diversified Files Definitive Proxy Materials

Diversified Energy Company has filed its Definitive Proxy Statement and additional proxy materials with the SEC for its 2026 Annual Meeting scheduled for May 6, 2026. The company is utilizing SEC rules for electronic access to proxy materials and has notified shareholders on how to participate virtually. Diversified Energy emphasizes its strategy o…

DEC
Yimutian Inc. Announces Resignation of Independent Director
Mar 25, 2026
Caleb Monroe
Press Releases

Yimutian Inc. Announces Resignation of Independent Director

Yimutian Inc., a leading agricultural B2B platform in China listed on NASDAQ, announced the resignation of independent director Junchen Sun for personal reasons. The company is actively seeking a replacement, with oversight from its Nominating and Corporate Governance Committee, and will disclose updates as required by SEC and NASDAQ regulations.

YMT
Rogers Communications Inc. Announces Pricing of Public Offering of US$750 million Fixed-to-Fixed Rate Subordinated Notes and Canadian Private Placement of Cdn$1.25 billion Fixed-to-Fixed Rate Subordinated Notes
Mar 24, 2026
Avery Klein
Press Releases

Rogers Communications Inc. Announces Pricing of Public Offering of US$750 million Fixed-to-Fixed Rate Subordinated Notes and Canadian Private Placement of Cdn$1.25 billion Fixed-to-Fixed Rate Subordinated Notes

Rogers Communications Inc. announced the pricing of a US$750 million public offering of fixed-to-fixed rate subordinated notes due 2056 in the U.S. and a C$1.25 billion private placement of similar notes in Canada. The net proceeds will be used to repay outstanding debt. Closings are expected on March 27, 2026.

RCI